PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER

本方案的目的是检查 动脉内氟代脱氧尿苷（FUDR）和口服亚叶酸， 改良肝动脉导管联合系统 5-氟尿嘧啶（5 FU）和α干扰素给药 结肠癌转移到肝脏 动脉内灌注 使用标准输注导管的FUDR产生高应答率， 与显著的肝毒性相关。 主要并发症 动脉内输注是意外的肝外输送 化疗、化学性肝炎、化学性胆囊炎和 可能致命的胆道硬化并发症 一种改良的肝 已经开发出一种动脉导管，其结果是产生湍流 在导管头端的气囊膨胀的过程。 肝气球 动脉导管产生湍流并允许输注液混合 与血液，并可能防止并发症与目前 使用导管。 转移性结肠癌的肝外进展 是与肝动脉灌注治疗相关的另一个问题。 一 非常有效的化学免疫治疗方案，包括5 FU和α 干扰素将与动脉内FUDR组合， 控制肝外转移性疾病。

The purpose of this protocol is to examine the efficacy and toxicity of intraarterial fluorogeoxyuridine (FUDR) and oral leucovorin using a modified hepatic artery catheter in combination with system administration of 5-fluorouracil (5FU) and alpha interferon for patients with colon cancer metastatic to the liver. Intraarterial infusion of FUDR using standard infusion catheters produces a high response rate but is associated with significant hepatic toxicity. The major complications of intraarterial infusion are accidental extra-hepatic delivery of chemotherapy, chemical hepatitis, chemical cholecystitis and a potentially lethal complication of biliary sclerosis. A modified hepatic artery catheter has been developed that produces turbulence as a result of the inflation of a balloon at the catheter tip. The balloon hepatic artery catheter produces turbulence and allows mixing of the infusate with blood and may prevent complications associated with the currently employed catheters. Extrahepatic progression of metastatic colon cancer is the other problem associated with hepatic artery infusion therapy. A very effective chemoimmunotherapy regimen consisting of 5FU and alpha interferon will be combined with intra-arterial FUDR in an attempt to control metastatic disease outside of the liver.